Language
中文
繁體
EN
About
Overview
Team
History
Branch
Honor
Culture
Science&Products
R & D Platform
Product pipeline
Product Introduction
Patient
Previous research
Patient Recruitment
Blog
Company News
Industry news
Investor
Prospectus
Financial report
Announcement and Circular
Corporate Governance
Investor Inquiry
Cooperation
Careers
Talent Strategy
Social Recruitment
Campus Recruitment
Contact
Message
English
español
Русский
Patient Area
Once again recognized! Immunotech Biopharm (06978.HK) has been awarded the honorary title of "Pioneer in Scientific and Technological Research in Hong Kong".
2022-03-15
Weekly Pharmaceutical News | Junshi and Hehuang face setbacks overseas, Johnson & Johnson's COVID-19 vaccine confirmed to have thrombotic side effects.
2022-05-11
Weekly Drug News | Eli Lilly's GIP/GLP-1 Dual Agonist Approved by FDA; Roche's TIGIT Target Fails Again
2022-05-19
Weekly Pharmaceutical News | The first report on domestically produced oral COVID-19 medication is released; Vilaprisan and Verzenios approved for market in China; Heng Rui makes further moves...
2022-05-26
Beijing Immunotech Biopharm and Shanghai Xinkaiyuan Precision are planning to establish a joint venture company, targeting the market for companion diagnostics in cancer treatment.
2022-06-06
Weekly Drug News | CStone Pharmaceuticals expands PD-L1 indications; GSK's bivalent HPV vaccine makes new progress; Innovent Biologics completes Phase I study of COVID-19 oral drug ahead of schedule.
Weekly Drug News | The world's first CD20/CD3 bispecific antibody launched; Empagliflozin adds new indications.
2022-06-17
Weekly Drug News | Roche's AD drug clinical trial fails; First oral alopecia areata drug launched; New drugs from AZ, Innovent and others reported for market launch.
2022-06-24
Weekly Drug News | Innovent's PD-1 Continues to Achieve Two New Indications, Shionogi's COVID-19 Oral Drug Approval Delayed
2022-07-01
Immunotech Biopharm (06978.HK) has achieved another milestone in digital construction: the medical management system is officially launched.
2022-07-05
